Patients With Multiple Myeloma (MM) Are Needed For A Research Study Using an Experimental Cellular Therapy

UVA Tracking #
Principal Investigator
Laahn H Foster
Contact Phone
Official Trial Title
Phase I/II Study of anti-CD3 x anti-SLAMF7 (anti-CS-1) Bispecific Antibody Armed Fresh Peripheral Blood Mononuclear Cells (SLAMF7 FPBMC) in Relapsed/Refractory Multiple Myeloma
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who have multiple myeloma (MM) who have received initial treatment but the treatment either didn’t work or stopped working. The purpose of this study is to better understand the safety and estimate the efficacy of an experimental cellular therapy (SLAMF7 FPBMC) in patients with multiple myeloma.

Participants will receive 8 weekly doses and then 8 more doses every 2 weeks of SLAMF7 FPBMC by intravenous infusion. Participants will be asked to provide research blood samples before, during, and after study treatment to look at immune response. Participants will still be followed after they have completed the study treatment, though some follow-up may be by phone or email if preferred. Study-specific tests that are being done beyond standard of care will be provided at no cost to the patient/participant or his/her/their insurance.

Additional information can be found here: MM FPBMC - or you can contact the study team at


No Compensation